Advances in anti-tumor therapy targeted type Ⅲ variant of the epidermal growth factor receptor mutation
- VernacularTitle:针对表皮生长因子受体Ⅲ型突变体的抗肿瘤研究进展
- Author:
xing-mei, ZHANG
;
yu-sheng, SHI
- Publication Type:Journal Article
- Keywords:
Receptor,epidermal growth factor;
Immunotherapy;
Neoplasms
- From:
Journal of International Oncology
2006;0(11):-
- CountryChina
- Language:Chinese
-
Abstract:
The epidermal growth factor receptor (EGFR) is overexpressed in many epithelial cancers,and is commonly caused by EGFR gene amplification and gene mutations. The most frequently occurring variant,the type III mutation (EGFRvIII) ,is characterized by an inframe deletion of exons 2-7 of the coding sequence. It is expressed only in tumors and not found in normal tissues, and therefore represents an attractive therapeutic target. The tumor therapy methods targeted for EGFRvIII include immu-notherapy, ribozyme, RNA interference, etc.
